aspirin has been researched along with Carotid Artery Narrowing in 219 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes." | 9.34 | Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 9.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs)." | 9.14 | Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o ( Bots, ML; Ford, I; Hennerici, MG; Laurent, S; Touboul, PJ, 2010) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 9.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 9.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "Clopidogrel is commonly used for secondary stroke prevention in patients with large vessel stenosis." | 8.02 | Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. ( Cohen, JE; Filioglo, A; Gomori, JM; Honig, A; Horev, A; Kalish, Y; Leker, RR; Sacagiu, T; Simaan, N, 2021) |
| " Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel." | 7.83 | Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016) |
| "Although different populations were examined for the incidence of aspirin resistance, the frequency and related risk factors for aspirin resistance in patients with metabolic syndrome have not been reported yet." | 7.74 | The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. ( Agacdiken, A; Baytugan, NZ; Kahraman, G; Kilic, T; Komsuoglu, B; Sahin, T; Ural, D; Ural, E, 2007) |
| "The CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial proved the effectiveness of the combination of clopidogrel and aspirin compared with aspirin alone in reducing presence and number of microembolic signals (MES) in patients with recently symptomatic carotid stenosis." | 7.73 | The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial. ( Dittrich, R; Droste, DW; Kaps, M; Larrue, V; Lees, K; Markus, HS; Nabavi, DG; Ringelstein, EB; Ritter, MA; Siebler, M, 2006) |
| "We recruited 131 patients with minor ischaemic stroke, within less than 7 days of stroke onset and a CYP2C19 loss-of-function allele, who had moderate-to-severe cerebral artery stenosis." | 6.94 | Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial. ( Chen, Q; Chu, W; Dong, M; Dou, L; Gao, B; Li, B; Li, J; Liu, C; Pan, Y; Song, H; Song, L; Wu, H, 2020) |
| " We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis." | 5.41 | Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Mac Grory, B; Rostanski, S; Yaghi, S, 2021) |
| "Aspirin resistance was more common in patients with MES (50% compared to 17." | 5.38 | Microembolic signals and aspirin resistance in patients with carotid stenosis. ( Dawson, J; Lees, KR; Quinn, T; Walters, MR, 2012) |
| "To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes." | 5.34 | Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. ( Bosch, J; Catanese, L; Connolly, SJ; Dyal, L; Eikelboom, JW; Hart, RG; Nayar, S; Ng, KKH; Perera, KS; Sharma, M; Yusuf, S, 2020) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 5.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| " In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone." | 5.22 | The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "Carotid endarterectomy and medical therapy (aspirin) were shown superior to medical therapy alone for asymptomatic (≥ 60%) carotid stenosis." | 5.20 | Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study. ( Boytsov, S; Deev, A; Dupik, N; Kolos, I; Loukianov, M, 2015) |
| " Patients with Helicobacter pylori infection and a history of peptic ulcer were assigned dual antiplatelet combination with omeprazole." | 5.17 | Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting. ( Chen, G; Du, Y; Hang, L; Ma, B, 2013) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs)." | 5.14 | Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o ( Bots, ML; Ford, I; Hennerici, MG; Laurent, S; Touboul, PJ, 2010) |
| "The clopidogrel plus aspirin for infarction reduction in acute stroke or transient ischaemic attack patients with large artery stenosis and microembolic signals (CLAIR) trial was a randomised, open-label, blinded-endpoint trial." | 5.14 | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. ( Chang, HM; Chen, C; Chollate, P; Fu, J; Han, Z; Hao, Q; Huang, YN; Koh, A; Markus, HS; Ratanakorn, D; Suwanwela, NC; Tan, KS; Wong, KS; Zhao, Y, 2010) |
| "Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) is a randomized, double-blind study in subjects with recently symptomatic > or =50% carotid stenosis." | 5.11 | Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. ( Droste, DW; Kaps, M; Larrue, V; Lees, KR; Markus, HS; Ringelstein, EB; Siebler, M, 2005) |
| "To determine the effectiveness of aspirin in preventing ischemic events in patients with asymptomatic carotid stenosis." | 5.08 | Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. ( Abrahamowicz, M; Battista, RN; Bourque, F; Côté, R; Langlois, Y; Mackey, A, 1995) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 5.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "We undertook a randomized controlled trial designed to compare the effects of carotid endarterectomy with medical treatment using low-dose aspirin in patients with asymptomatic carotid stenosis." | 5.07 | Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group. ( , 1992) |
| " Data from one randomised controlled trial showed no significant difference in benefit with aspirin versus placebo in asymptomatic carotid stenosis, but it is still reasonable to recommend aspirin (81-325 mg daily) for prevention of vascular events in these patients." | 5.01 | Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. ( de Borst, GJ; Halliday, A; Hamilton, G; Kakkos, S; McCabe, DJH; Murphy, SJX; Naylor, AR; Ricco, JB; Sillesen, H; Vega de Ceniga, M, 2019) |
| "Drugs that prevent platelets from sticking together-ie, aspirin, dipyridamole, and clopidogrel-are an important part of therapy to prevent recurrence of ischemic stroke of atherosclerotic origin." | 4.89 | Antiplatelet therapy to prevent recurrent stroke: Three good options. ( Mansoor, AH; Mujtaba, MT; Silver, B, 2013) |
| " Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive." | 4.85 | Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| " (1) Proven: one or more TIAs in the past 6 months and carotid stenosis > or = 70% or mild stroke within 6 months and a carotid stenosis > or = 70%; (2) acceptable but not proven: TIAs within the past 6 months and a stenosis 50% to 69%, progressive stroke and a stenosis > or = 70%, mild or moderate stroke in the past 6 months and a stenosis 50% to 69%, or carotid endarterectomy ipsilateral to TIAs and a stenosis > or = 70% combined with required coronary artery bypass grafting; (3) uncertain: TIAs with a stenosis < 50%, mild stroke and stenosis < 50%, TIAs with a stenosis < 70% combined with coronary artery bypass grafting, or symptomatic, acute carotid thrombosis; (4) proven inappropriate: moderate stroke with stenosis < 50%, not on aspirin; single TIA, < 50% stenosis, not on aspirin; high-risk patient with multiple TIAs, not on aspirin, stenosis < 50%; high-risk patient, mild or moderate stroke, stenosis < 50%, not on aspirin; global ischemic symptoms with stenosis < 50%; acute dissection, asymptomatic on heparin." | 4.79 | Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. ( Barnett, HJ; Beebe, HG; Bernstein, EF; Brener, BJ; Brott, T; Caplan, LR; Day, A; Goldstone, J; Hobson, RW; Moore, WS, 1995) |
| " We aim to compare rates of postoperative bleeding, stroke and major adverse events (stroke, death or MI) among patients on Aspirin alone (ASAA) versus DAPT (Clopidogrel and Aspirin)." | 4.31 | Dual Antiplatelet Therapy Is Associated with Increased Risk of Bleeding and Decreased Risk of Stroke Following Carotid Endarterectomy. ( Dakour, H; Elsayed, N; Malas, MB; Marmor, R; Patel, RJ; Ramachandran, M, 2023) |
| "Compared with aspirin/clopidogrel, aspirin/ticagrelor was associated with a potentially lower risk of stroke/death and bleeding complications after CAS in cases in which protamine was used but a higher risk of these outcomes in the absence of protamine." | 4.12 | Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting. ( Jim, J; Liang, P; Marcaccio, CL; Patel, PB; Rastogi, V; Schermerhorn, ML; Schneider, PA; Stangenberg, L, 2022) |
| "Clopidogrel is commonly used for secondary stroke prevention in patients with large vessel stenosis." | 4.02 | Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. ( Cohen, JE; Filioglo, A; Gomori, JM; Honig, A; Horev, A; Kalish, Y; Leker, RR; Sacagiu, T; Simaan, N, 2021) |
| "A total of 176 patients taking antiplatelet medications aspirin and/or clopidogrel with peripheral artery disease (PAD) and/or carotid stenosis (CS) were included in the study." | 3.96 | Perioperative changes of response to antiplatelet medication in vascular surgery patients. ( Breuer-Kaiser, A; Düsterwald, JO; Hummel, T; Meves, SH; Mühlberger, D; Mumme, A; Neubauer, H, 2020) |
| "A retrospective, single center, cohort study was carried out of 32 patients who underwent eCAS (18 received tirofiban, 14 received aspirin) at our comprehensive stroke center (2008-2016)." | 3.91 | Acute administration of tirofiban versus aspirin in emergent carotid artery stenting. ( Berberat, J; Diepers, M; Gruber, P; Hlavica, M; Kahles, T; Nedeltchev, K; Remonda, L; Victor Ineichen, B, 2019) |
| " Diabetes mellitus and current smoker status were independent factors related to reactivity to clopidogrel." | 3.83 | Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures. ( Hironaka, Y; Kichikawa, K; Motoyama, Y; Nakagawa, I; Nakase, H; Park, HS; Takayama, K; Wada, T; Yokoyama, S, 2016) |
| "Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index." | 3.77 | Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. ( Alexander, MJ; Choulakian, A; Drazin, D; Kornbluth, P; Nuño, M, 2011) |
| "Although different populations were examined for the incidence of aspirin resistance, the frequency and related risk factors for aspirin resistance in patients with metabolic syndrome have not been reported yet." | 3.74 | The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. ( Agacdiken, A; Baytugan, NZ; Kahraman, G; Kilic, T; Komsuoglu, B; Sahin, T; Ural, D; Ural, E, 2007) |
| "The CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial proved the effectiveness of the combination of clopidogrel and aspirin compared with aspirin alone in reducing presence and number of microembolic signals (MES) in patients with recently symptomatic carotid stenosis." | 3.73 | The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial. ( Dittrich, R; Droste, DW; Kaps, M; Larrue, V; Lees, K; Markus, HS; Nabavi, DG; Ringelstein, EB; Ritter, MA; Siebler, M, 2006) |
| "(1) Aspirin reduces the risk of myocardial infarction in men over 40 with no history of cardiovascular disease, and in hypertensive patients of both sexes over that age." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention. ( , 2000) |
| " In addition, the antithrombotic effects of SK&F 106760 were compared with those of aspirin in an acute canine model of extracranial carotid artery thrombosis with high-grade stenosis." | 3.68 | Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. ( Feuerstein, GZ; Nichols, AJ; Ohlstein, EH; Rycyna, R; Sarkar, S; Sauermelch, CF; Willette, RN, 1992) |
| "Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| "We recruited 131 patients with minor ischaemic stroke, within less than 7 days of stroke onset and a CYP2C19 loss-of-function allele, who had moderate-to-severe cerebral artery stenosis." | 2.94 | Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial. ( Chen, Q; Chu, W; Dong, M; Dou, L; Gao, B; Li, B; Li, J; Liu, C; Pan, Y; Song, H; Song, L; Wu, H, 2020) |
| "Aspirin-HTPR was noted in 9." | 2.82 | Platelet Biomarkers in Patients with Atherosclerotic Extracranial Carotid Artery Stenosis: A Systematic Review. ( de Borst, GJ; Delaney, S; Hamilton, G; Kinsella, JA; McCabe, DJH; McMahon, J; Murphy, SJX; Naylor, AR; Offiah, C; Smith, DR; Subramanian, A, 2022) |
| "aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents." | 2.82 | Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022) |
| "Strokes are infrequent but potentially serious complications following carotid intervention, but antiplatelet therapy can reduce these risks." | 2.82 | Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2. ( Bulbulia, R; Coppi, G; de Borst, GJ; Halliday, A; Huibers, A, 2016) |
| "To investigate the effect of removing phlegm and dispelling stasis method (RPDSM) combined with Western medicine for treatment of cerebrovascular stenosis." | 2.73 | [Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis]. ( Gao, L; Liu, Q; Wang, PP, 2008) |
| "In patients with symptomatic carotid artery stenosis, high-intensity transient signals detected by transcranial Doppler (TCD) have been related to particulate microemboli originating at the stenotic lesion." | 2.70 | Acetylsalicylic acid and microembolic events detected by transcranial Doppler in symptomatic arterial stenoses. ( Blaser, T; Goertler, M; Krueger, S; Lutze, G; Wallesch, CW, 2001) |
| "Nine patients with recent transient ischemic attack or minor stroke of arterial origin were investigated." | 2.69 | Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. ( Baeumer, M; Blaser, T; Goertler, M; Jost, S; Kross, R; Lutze, G; Wallesch, CW, 1999) |
| "Initially, transient ischemic attack or cerebral infarction occurring in the distribution of the study artery and any transient ischemic attack, stroke, or death occurring in the perioperative period." | 2.68 | Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. ( , 1995) |
| "In addition, 6 transient ischemic attacks and 3 myocardial infarctions could be directly linked to CEA, for a total CEA event rate of 2." | 2.68 | An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. ( Broderick, JP; Cohen, SN; Dempsey, RJ; Ernst, CB; Hosking, JD; Moore, WS; Robertson, JT; Toole, JF; Young, B, 1996) |
| " Twenty-six patients were dosed for 2 weeks, 300 mg aspirin once daily and then for 2 weeks, 250 mg ticlopidine twice daily." | 2.68 | Asymptomatic circulating cerebral emboli and cerebral blood flow velocity under aspirin and ticlopidine in patients with cerebrovascular disease. ( Droste, DW; Kaps, M; Siemens, HJ; Sonne, M, 1996) |
| "The CASANOVA study (Carotid Artery Stenosis with Asymptomatic Narrowing: Operation Versus Aspirin) is a multicenter trial in 410 patients with asymptomatic stenosis (50-90%) of the internal carotid artery who were randomized after angiography." | 2.67 | Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group. ( , 1991) |
| "We prospectively analyzed adverse effects of aspirin in a multicentered cooperative study undertaken to determine the role of endarterectomy in the treatment of asymptomatic carotid artery stenosis." | 2.67 | Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis. The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group. ( Corson, JD; Hobson, RW; Krupski, WC; Rapp, JH; Weiss, DG, 1992) |
| "Carotid stenosis was confirmed by arteriography, which demonstrated at least 50% stenosis, measured by comparing the least transverse diameter of the stenosis on lateral arteriography." | 2.67 | 4. Current status of operative treatment for asymptomatic carotid stenosis. ( Hobson, RW; Towne, JB, 1994) |
| "Patients with carotid stenosis have a high frequency of asymptomatic coronary artery disease (CAD)." | 2.67 | Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167. ( Chimowitz, MI; Cohen, SL; Hobson, RW; Starling, MR; Weiss, DG, 1994) |
| "Patients suffering from carotid artery stenosis symptomatic or not." | 2.48 | Carotid endarterectomy plus medical therapy or medical therapy alone for carotid artery stenosis in symptomatic or asymptomatic patients: a meta-analysis. ( Guay, J; Ochroch, EA, 2012) |
| "Ischemic stroke is a common complication after CABG." | 2.44 | Prevention of ischemic stroke: surgery. ( Chaturvedi, S; Rajamani, K, 2007) |
| "Extracranial internal carotid artery stenosis (EICAS) accounts for approximately 25% of ischemic strokes, with an incidence as high as 10% in people aged > 80 years." | 2.44 | Multimodality management of carotid artery stenosis: reviewing the class-I evidence. ( McClelland, S, 2007) |
| "Twenty-three children had varicella at age 1." | 2.43 | Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005) |
| "The risk of TIA or stroke recurrence reaches 30-45%." | 2.42 | [Stenosis of the carotid arteries]. ( Kaźmierski, MK, 2003) |
| "The diagnosis of carotid stenosis is made after occurrence of a cerebral ischemic event or during an angiologic examination, mainly using Doppler/Duplex-sonography." | 2.42 | [Carotid stenosis: diagnosis, patient selection, therapy]. ( Barth, A, 2003) |
| "Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid)." | 2.40 | Triflusal. ( Goa, KL; McNeely, W, 1998) |
| " Furthermore, in assessing the potential benefits of long-term use of ASA for prophylactic purposes in these patients, one should also evaluate the side-effects and intolerance related to its chronic use, as well as its potential complications especially from a gastrointestinal perspective." | 2.39 | Aspirin in asymptomatic carotid disease. ( Côté, R, 1994) |
| "The majority presented with recurrent transient ischemic attacks/minor strokes within a single vascular territory over days to weeks." | 1.56 | Focal Cerebral Arteriopathy in Young Adult Patients With Stroke. ( Cronin, S; Fanning, N; McKenna, MC, 2020) |
| "All the patients presented with carotid artery stenosis >70% (North American Symptomatic Carotid Endarterectomy Trial [NASCET] criteria), which was symptomatic in 42 patients (transient ischemic attack, n = 32; minor stroke, n = 10) and asymptomatic in 146." | 1.46 | Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study. ( Calio', FG; Illuminati, G; Masci, F; Pizzardi, G; Ricco, JB; Schneider, F, 2017) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| " The purpose of this study was to compare the efficacy and safety of clopidogrel combined with aspirin (CA) versus sarpogrelate combined with aspirin (SA) treatment in carotid endarterectomy (CEA) patients." | 1.43 | Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study. ( Gu, Y; Guo, J; Guo, L; Qi, L; Tong, Z; Wang, Z; Yu, H; Zhang, J, 2016) |
| " Long-term use of aspirin plus clopidorel after CAS did not decrease the risk of ischemic stroke, composite vascular events, or death during 6 months of follow-up." | 1.42 | Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial? ( Huang, JY; Jhang, KM; Jian, ZH; Ku, WY; Liaw, YP; Nfor, ON; Tung, YC, 2015) |
| "A total of 949 patients with cervical carotid artery stenosis were enrolled at 43 institutions in Japan; 934 who had undergone CAS with antiplatelet drugs and followed for 1 year were analyzed." | 1.40 | Prospective registry of carotid artery stenting in Japan--investigation on device and antiplatelet for carotid artery stenting. ( Ezura, M; Hyodo, A; Matsubara, Y; Matsumaru, Y; Matsumoto, Y; Miyachi, S; Nakamura, M; Okada, Y; Sakai, C; Sakai, N; Terada, T; Yamagami, H; Yokoi, H, 2014) |
| "In the Asymptomatic Carotid Artery Stenosis trial (1995), medical management was defined as aspirin in addition to adequate control of comorbidities." | 1.39 | Efficacy of contemporary medical management for asymptomatic carotid artery stenosis. ( Ahn, JE; Chang, J; Chun, L; Landsman, N; Patel, KK; Rhee, K, 2013) |
| "Onyx HD-500 is a liquid embolic used to treat intracranial aneurysms." | 1.39 | Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment. ( Alaraj, A; Aletich, VA; Amin-Hanjani, S; Carlson, AP; Charbel, FT, 2013) |
| "Aspirin resistance was more common in patients with MES (50% compared to 17." | 1.38 | Microembolic signals and aspirin resistance in patients with carotid stenosis. ( Dawson, J; Lees, KR; Quinn, T; Walters, MR, 2012) |
| "Cerebral infarction associated with ulcerative colitis is particularly rare, but clinically important because of its high morbidity and mortality." | 1.37 | Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a). ( Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P, 2011) |
| "Freedom from repeat intervention for re-recurrence was 89% in the CEA group and 95% in the CAS group (p=0." | 1.36 | Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies. ( Attigah, N; Böckler, D; Deyle, C; Geisbüsch, P; Hartmann, M; Külkens, S; Ringleb, P, 2010) |
| "Aspirin was without significant effect." | 1.34 | Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. ( Brandl, R; Deckmyn, H; Penz, SM; Reininger, AJ; Siess, W; Toth, O, 2007) |
| "Aspirin resistance was defined as closure time (CT) less than the upper limit of normal (158 s collagen/epinephrine agonist; 118 s collagen/adenosine diphosphate (ADP) agonist)." | 1.33 | Point of care testing of aspirin resistance in patients with vascular disease. ( Appleberg, M; Lewis, DR; Ward, CM; Wong, S, 2006) |
| "To report procedure-related complications and neurological adverse events of unprotected over-the-wire (OTW) and protected rapid exchange (RX) carotid artery stenting (CAS) in a single-center patient series during an 8-year period." | 1.33 | Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series. ( Ahmadi, A; Amighi, J; Boltuch, J; Dick, P; Minar, E; Mlekusch, W; Sabeti, S; Schillinger, M; Schlager, O, 2005) |
| "Acute in-stent thrombosis is a well-known complication of carotid angioplasty and stenting (CAS) and often due to resistance to or inadequate treatment with platelet-inhibiting agents." | 1.33 | Late in-stent thrombosis following carotid angioplasty and stenting. ( Buhk, JH; Knauth, M; Wellmer, A, 2006) |
| "A plaque embolism was excluded clinically and in the contrast-medium intensified MRT 5 days after the intervention in 79/81 (97." | 1.32 | [Outpatient primary stent-angioplasty in symptomatic internal carotid artery stenoses]. ( Andresen, R; Brinckmann, W; Roth, M, 2003) |
| "Treatment of dissecting pseudoaneurysms of the distal cervical internal carotid artery with preservation of the parent artery by using stents or coils has become routine." | 1.32 | Stent-coil treatment of a distal internal carotid artery dissecting pseudoaneurysm on a redundant loop by use of a flexible, dedicated nitinol intracranial stent. ( Graybeal, CL; Pride, GL; Purdy, P; Rappard, G; Replogle, RE; White, J, 2004) |
| "An 18-year-old Saudi male with systemic lupus erythematosus (SLE) presented with mild right hemiparesis, followed by recurrent ischemic stroke." | 1.31 | Systemic lupus erythematosus associated with moyamoya syndrome. ( Al Rayes, HM; El Ramahi, KM, 2000) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| "Macrophage density in carotid artery plaques classified by B-mode ultrasound imaging as echolucent (n = 56), intermediate (n = 25), or echorich (n = 25) was 1." | 1.31 | Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. ( Bentzon, J; Falk, E; Grønholdt, ML; Nordestgaard, BG; Sillesen, H; Wiebe, BM; Zhou, J, 2002) |
| "Most of cerebral infarctions were observed in the hemisphere, ipsilateral to the irradiated carotid artery." | 1.29 | Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits. ( Fujimura, M; Mikashima, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 60 (27.40) | 18.2507 |
| 2000's | 77 (35.16) | 29.6817 |
| 2010's | 60 (27.40) | 24.3611 |
| 2020's | 22 (10.05) | 2.80 |
| Authors | Studies |
|---|---|
| Marcaccio, CL | 2 |
| Patel, PB | 2 |
| Liang, P | 2 |
| Rastogi, V | 2 |
| Stangenberg, L | 2 |
| Jim, J | 2 |
| Schneider, PA | 2 |
| Schermerhorn, ML | 2 |
| Subramanian, A | 1 |
| Delaney, S | 1 |
| Murphy, SJX | 3 |
| Smith, DR | 1 |
| Offiah, C | 1 |
| McMahon, J | 1 |
| de Borst, GJ | 3 |
| Naylor, AR | 4 |
| Hamilton, G | 4 |
| Kinsella, JA | 3 |
| McCabe, DJH | 4 |
| Ku, JC | 1 |
| Taslimi, S | 1 |
| Zuccato, J | 1 |
| Pasarikovski, CR | 1 |
| Nasr, N | 1 |
| Chechik, O | 1 |
| Chisci, E | 1 |
| Bissacco, D | 1 |
| Larrue, V | 3 |
| Rabinovich, Y | 1 |
| Michelagnoli, S | 1 |
| Settembrini, PG | 1 |
| Priola, SM | 1 |
| Cusimano, MD | 1 |
| Yang, VXD | 1 |
| Macdonald, RL | 1 |
| Patel, RJ | 1 |
| Marmor, R | 1 |
| Dakour, H | 1 |
| Elsayed, N | 1 |
| Ramachandran, M | 1 |
| Malas, MB | 1 |
| Chen, P | 1 |
| Lazar, A | 1 |
| Ding, J | 1 |
| Siracuse, JJ | 1 |
| Patel, VI | 3 |
| Morrissey, NJ | 1 |
| Marnat, G | 1 |
| Finistis, S | 1 |
| Moreno, R | 1 |
| Sibon, I | 1 |
| Pop, R | 1 |
| Mazighi, M | 2 |
| Clarençon, F | 1 |
| Rosso, C | 1 |
| Dargazanli, C | 1 |
| Darcourt, J | 1 |
| Olivot, JM | 2 |
| Boulouis, G | 1 |
| Janot, K | 1 |
| Moulin, S | 1 |
| Bourcier, R | 1 |
| Consoli, A | 1 |
| Richard, S | 1 |
| Arquizan, C | 1 |
| Vannier, S | 1 |
| Richter, S | 1 |
| Gentric, JC | 1 |
| Papagiannaki, C | 1 |
| Naggara, O | 1 |
| Eker, OF | 1 |
| Lapergue, B | 1 |
| Caroff, J | 1 |
| Gory, B | 1 |
| Wyers, MC | 1 |
| Simonte, G | 1 |
| Guglielmini, G | 1 |
| Falcinelli, E | 1 |
| Isernia, G | 1 |
| Mezzasoma, AM | 1 |
| Gresele, P | 1 |
| Lenti, M | 1 |
| Manunga, J | 1 |
| Pedersen, C | 1 |
| Stanberry, L | 1 |
| Pai, A | 1 |
| Skeik, N | 1 |
| Sullivan, TM | 1 |
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Perera, KS | 1 |
| Ng, KKH | 1 |
| Nayar, S | 1 |
| Catanese, L | 1 |
| Dyal, L | 1 |
| Sharma, M | 1 |
| Connolly, SJ | 1 |
| Yusuf, S | 1 |
| Bosch, J | 1 |
| Eikelboom, JW | 1 |
| Hart, RG | 4 |
| Lim, ST | 1 |
| Tierney, S | 2 |
| Egan, B | 2 |
| Feeley, TM | 2 |
| Murphy, SM | 1 |
| Walsh, RA | 1 |
| Collins, DR | 1 |
| Coughlan, T | 2 |
| O'Neill, D | 2 |
| Harbison, JA | 2 |
| Madhavan, P | 2 |
| O'Neill, SM | 2 |
| Colgan, MP | 2 |
| Cox, D | 1 |
| Moran, N | 2 |
| Meaney, JF | 1 |
| Murias, E | 1 |
| Vega, P | 1 |
| Lopez-Cancio, E | 1 |
| Peña, J | 1 |
| Morales, E | 1 |
| Benavente, L | 1 |
| González, M | 1 |
| Larrosa, D | 1 |
| Rico, M | 1 |
| Riesco, N | 1 |
| Cadenas, M | 1 |
| Jimenez, JM | 1 |
| Chaviano, J | 1 |
| Saiz, A | 1 |
| Calleja, S | 1 |
| Arias, F | 1 |
| McKenna, MC | 1 |
| Fanning, N | 1 |
| Cronin, S | 1 |
| Wu, H | 1 |
| Song, H | 1 |
| Dou, L | 1 |
| Gao, B | 1 |
| Pan, Y | 1 |
| Dong, M | 1 |
| Chen, Q | 1 |
| Li, J | 1 |
| Song, L | 1 |
| Liu, C | 1 |
| Li, B | 1 |
| Chu, W | 1 |
| Delvoye, F | 1 |
| Maier, B | 1 |
| Escalard, S | 1 |
| Labreuche, J | 1 |
| Thion, LA | 1 |
| Aknouche, S | 1 |
| Hebert, S | 1 |
| Redjem, H | 1 |
| Smajda, S | 1 |
| Ciccio, G | 1 |
| Allard, J | 1 |
| Sabben, C | 1 |
| Obadia, M | 1 |
| Maertens de Noordhout, A | 1 |
| Blanc, R | 1 |
| Piotin, M | 1 |
| Desilles, JP | 1 |
| Hummel, T | 2 |
| Meves, SH | 2 |
| Breuer-Kaiser, A | 1 |
| Düsterwald, JO | 1 |
| Mühlberger, D | 2 |
| Mumme, A | 2 |
| Neubauer, H | 2 |
| Horev, A | 2 |
| Zlotnik, Y | 1 |
| Borodetsky, V | 1 |
| Biederko, R | 1 |
| Star, M | 1 |
| Zvenigorodsky, V | 1 |
| Shelef, I | 1 |
| Ifergane, G | 1 |
| Honig, A | 1 |
| Sacagiu, T | 1 |
| Filioglo, A | 1 |
| Simaan, N | 1 |
| Kalish, Y | 1 |
| Gomori, JM | 1 |
| Leker, RR | 1 |
| Cohen, JE | 2 |
| Yaghi, S | 1 |
| de Havenon, A | 1 |
| Rostanski, S | 1 |
| Kvernland, A | 1 |
| Mac Grory, B | 1 |
| Furie, KL | 1 |
| Kim, AS | 1 |
| Easton, JD | 2 |
| Johnston, SC | 3 |
| Henninger, N | 1 |
| Ciolli, L | 1 |
| Lelli, N | 1 |
| Rosafio, F | 1 |
| Maffei, S | 1 |
| Sacchetti, F | 1 |
| Vandelli, L | 1 |
| Dell'Acqua, ML | 1 |
| Picchetto, L | 1 |
| Borzì, GM | 1 |
| Ricceri, R | 1 |
| Pentore, R | 1 |
| Tondelli, M | 1 |
| Vandelli, G | 1 |
| Rodríguez-Villatoro, N | 1 |
| Meletti, S | 1 |
| Zini, A | 1 |
| Vallone, S | 1 |
| Bigliardi, G | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Oliver Tobin, W | 1 |
| Ronan Collins, D | 1 |
| Doherty, CP | 1 |
| Moore, DJ | 1 |
| Saqqur, M | 1 |
| Murphy, RP | 1 |
| Amarenco, P | 1 |
| Albers, GW | 1 |
| Denison, H | 1 |
| Evans, SR | 1 |
| Held, P | 1 |
| Hill, MD | 1 |
| Jonasson, J | 1 |
| Kasner, SE | 1 |
| Ladenvall, P | 1 |
| Minematsu, K | 1 |
| Molina, CA | 1 |
| Wang, Y | 1 |
| Wong, KSL | 1 |
| Tanaskovic, S | 1 |
| Radak, D | 1 |
| Aleksic, N | 1 |
| Calija, B | 1 |
| Maravic-Stojkovic, V | 1 |
| Nenezic, D | 1 |
| Ilijevski, N | 1 |
| Popov, P | 1 |
| Vucurevic, G | 1 |
| Babic, S | 1 |
| Matic, P | 1 |
| Gajin, P | 1 |
| Vasic, D | 1 |
| Rancic, Z | 1 |
| Gruber, P | 1 |
| Hlavica, M | 1 |
| Berberat, J | 1 |
| Victor Ineichen, B | 1 |
| Diepers, M | 1 |
| Nedeltchev, K | 2 |
| Kahles, T | 1 |
| Remonda, L | 1 |
| Ricco, JB | 2 |
| Sillesen, H | 3 |
| Kakkos, S | 1 |
| Halliday, A | 2 |
| Vega de Ceniga, M | 1 |
| Christodoulou, C | 1 |
| Economides, C | 1 |
| D'Cruz, D | 1 |
| Kolos, I | 1 |
| Loukianov, M | 1 |
| Dupik, N | 1 |
| Boytsov, S | 1 |
| Deev, A | 1 |
| Sorkin, GC | 1 |
| Dumont, TM | 1 |
| Wach, MM | 1 |
| Eller, JL | 1 |
| Mokin, M | 1 |
| Natarajan, SK | 1 |
| Baxter, MS | 1 |
| Snyder, KV | 1 |
| Levy, EI | 2 |
| Hopkins, LN | 1 |
| Siddiqui, AH | 1 |
| Conrad, MF | 3 |
| Boulom, V | 1 |
| Baloum, V | 1 |
| Mukhopadhyay, S | 1 |
| Garg, A | 1 |
| Cambria, RP | 3 |
| Wadiwala, MF | 1 |
| Kamal, AK | 1 |
| Turan, TN | 3 |
| Smock, A | 1 |
| Chimowitz, MI | 4 |
| Chang, J | 1 |
| Ahn, JE | 1 |
| Landsman, N | 1 |
| Rhee, K | 1 |
| Chun, L | 1 |
| Patel, KK | 1 |
| Derdeyn, CP | 3 |
| Lynn, MJ | 2 |
| Fiorella, D | 2 |
| Janis, LS | 2 |
| Montgomery, J | 2 |
| Nizam, A | 1 |
| Lane, BF | 2 |
| Lutsep, HL | 2 |
| Barnwell, SL | 1 |
| Waters, MF | 1 |
| Hoh, BL | 1 |
| Hourihane, JM | 1 |
| Alexandrov, AV | 1 |
| Harrigan, MR | 1 |
| Chiu, D | 1 |
| Klucznik, RP | 1 |
| Clark, JM | 1 |
| McDougall, CG | 1 |
| Johnson, MD | 1 |
| Pride, GL | 2 |
| Lynch, JR | 1 |
| Zaidat, OO | 1 |
| Rumboldt, Z | 1 |
| Cloft, HJ | 1 |
| Nakagawa, I | 3 |
| Wada, T | 3 |
| Park, HS | 3 |
| Nishimura, F | 1 |
| Yamada, S | 2 |
| Nakagawa, H | 1 |
| Kichikawa, K | 3 |
| Nakase, H | 3 |
| Bakri, SJ | 1 |
| Luqman, A | 1 |
| Pathik, B | 1 |
| Chandrasekaran, K | 1 |
| Mansoor, AH | 1 |
| Mujtaba, MT | 1 |
| Silver, B | 1 |
| Alcocer, F | 1 |
| Novak, Z | 1 |
| Combs, BR | 1 |
| Lowman, B | 1 |
| Passman, MA | 1 |
| Mujib, M | 1 |
| Jordan, WD | 1 |
| Sakai, N | 1 |
| Yamagami, H | 1 |
| Matsubara, Y | 1 |
| Ezura, M | 1 |
| Hyodo, A | 1 |
| Matsumaru, Y | 1 |
| Miyachi, S | 1 |
| Okada, Y | 1 |
| Terada, T | 1 |
| Yokoi, H | 1 |
| Nakamura, M | 1 |
| Matsumoto, Y | 1 |
| Sakai, C | 1 |
| Ma, B | 1 |
| Hang, L | 1 |
| Chen, G | 1 |
| Du, Y | 1 |
| Abbott, A | 1 |
| Geroulakos, G | 1 |
| Mikhailidis, DP | 1 |
| Nicolaides, AN | 1 |
| Veith, FJ | 2 |
| Michalczyk, MJ | 1 |
| Opalacz, A | 1 |
| LaMuraglia, GM | 1 |
| Yan, Y | 1 |
| Yuan, Y | 1 |
| Liang, L | 1 |
| Chen, T | 1 |
| Shen, Y | 1 |
| Zhong, C | 1 |
| Paraskevas, KI | 1 |
| Lewszuk, AJ | 1 |
| Postuła, M | 1 |
| Madycki, G | 1 |
| Staszkiewicz, W | 1 |
| Opolski, G | 1 |
| Eberhardt, A | 1 |
| Amato, B | 1 |
| Compagna, R | 1 |
| Amato, M | 1 |
| Gallelli, L | 1 |
| de Franciscis, S | 1 |
| Serra, R | 1 |
| Batchelder, A | 1 |
| Hunter, J | 1 |
| Cairns, V | 1 |
| Sandford, R | 1 |
| Munshi, A | 1 |
| Nishi, H | 1 |
| Nakahara, I | 1 |
| Matsumoto, S | 1 |
| Hashimoto, T | 1 |
| Ohta, T | 1 |
| Sadamasa, N | 1 |
| Ishibashi, R | 1 |
| Gomi, M | 1 |
| Saka, M | 1 |
| Miyata, H | 1 |
| Watanabe, S | 1 |
| Okata, T | 1 |
| Sonoda, K | 1 |
| Kouge, J | 1 |
| Ishii, A | 2 |
| Nagata, I | 1 |
| Kira, J | 1 |
| Cotsonis, GA | 1 |
| Jhang, KM | 1 |
| Huang, JY | 1 |
| Nfor, ON | 1 |
| Jian, ZH | 1 |
| Tung, YC | 1 |
| Ku, WY | 1 |
| Liaw, YP | 1 |
| Yokoyama, S | 2 |
| Hironaka, Y | 1 |
| Motoyama, Y | 2 |
| Takayama, K | 1 |
| Huibers, A | 1 |
| Bulbulia, R | 1 |
| Coppi, G | 1 |
| Shahidi, S | 1 |
| Owen-Falkenberg, A | 1 |
| Gottschalksen, B | 1 |
| Ellemann, K | 1 |
| Rüdiger, K | 1 |
| Mügge, A | 1 |
| Burkert, B | 1 |
| Guo, J | 1 |
| Gu, Y | 1 |
| Guo, L | 1 |
| Yu, H | 1 |
| Qi, L | 1 |
| Tong, Z | 1 |
| Zhang, J | 1 |
| Wang, Z | 1 |
| Deng, QQ | 1 |
| Tang, J | 1 |
| Chen, C | 2 |
| Markus, H | 1 |
| Huang, YN | 2 |
| Zhao, H | 1 |
| Ratanakorn, D | 2 |
| Wong, KS | 3 |
| Fu, JH | 1 |
| Illuminati, G | 1 |
| Schneider, F | 1 |
| Pizzardi, G | 1 |
| Masci, F | 1 |
| Calio', FG | 1 |
| Turtzo, LC | 1 |
| McCullough, LD | 1 |
| Guerra, M | 1 |
| Mota, JC | 1 |
| Veloso, M | 1 |
| Gama, V | 1 |
| Vouga, L | 1 |
| Yamasaki, H | 1 |
| Matsubara, S | 2 |
| Sasaki, I | 1 |
| Nagahiro, S | 1 |
| Beckman, JA | 1 |
| Tautenhahn, J | 1 |
| Meyer, F | 1 |
| Pech, M | 1 |
| Michael, L | 1 |
| Goertler, M | 3 |
| Halloul, Z | 1 |
| Attigah, N | 1 |
| Külkens, S | 1 |
| Deyle, C | 1 |
| Ringleb, P | 1 |
| Hartmann, M | 1 |
| Geisbüsch, P | 1 |
| Böckler, D | 1 |
| Fu, J | 1 |
| Chang, HM | 1 |
| Suwanwela, NC | 1 |
| Han, Z | 1 |
| Tan, KS | 1 |
| Chollate, P | 1 |
| Zhao, Y | 1 |
| Koh, A | 1 |
| Hao, Q | 1 |
| Markus, HS | 4 |
| Hennerici, MG | 2 |
| Bots, ML | 1 |
| Ford, I | 1 |
| Laurent, S | 1 |
| Touboul, PJ | 1 |
| Itshayek, E | 1 |
| Ogasawara, K | 1 |
| Ahn, CM | 1 |
| Hong, SJ | 1 |
| Park, JH | 1 |
| Kim, JS | 1 |
| Lim, DS | 1 |
| Farina, A | 1 |
| Spinazzola, A | 1 |
| Abbiati, G | 1 |
| Arpini, MT | 1 |
| Bergamaschi, L | 1 |
| Riva, A | 1 |
| Berticelli, P | 1 |
| Poisson, S | 1 |
| Calabrò, RS | 1 |
| Pezzini, A | 1 |
| Gervasi, G | 1 |
| Pollicino, P | 1 |
| Bramanti, P | 1 |
| Leung, TW | 1 |
| Yu, SC | 1 |
| Dawson, J | 1 |
| Quinn, T | 1 |
| Lees, KR | 2 |
| Walters, MR | 1 |
| Drazin, D | 1 |
| Choulakian, A | 1 |
| Nuño, M | 1 |
| Kornbluth, P | 1 |
| Alexander, MJ | 1 |
| Pelegrín, L | 1 |
| Mesquida, M | 1 |
| Rey, A | 1 |
| Sánchez-Dalmau, B | 1 |
| Frohman, L | 1 |
| Inoue, Y | 1 |
| Krings, T | 1 |
| Rogers, RK | 1 |
| Sakhuja, R | 1 |
| Margey, R | 1 |
| Stone, JH | 1 |
| Rosenfield, K | 1 |
| Jaff, MR | 1 |
| Guay, J | 1 |
| Ochroch, EA | 1 |
| Schoenefeld, E | 1 |
| Donas, K | 1 |
| Radicke, A | 1 |
| Osada, N | 1 |
| Austermann, M | 1 |
| Torsello, G | 1 |
| Vellimana, AK | 1 |
| Kadkhodayan, Y | 1 |
| Rich, KM | 1 |
| Cross, DT | 1 |
| Moran, CJ | 1 |
| Zazulia, AR | 1 |
| Lee, JM | 1 |
| Chicoine, MR | 1 |
| Dacey, RG | 1 |
| Zipfel, GJ | 1 |
| Carlson, AP | 1 |
| Alaraj, A | 1 |
| Amin-Hanjani, S | 1 |
| Charbel, FT | 1 |
| Aletich, VA | 1 |
| Spence, JD | 2 |
| Lopez-Yunez, AM | 1 |
| Baumgartner, RW | 3 |
| Georgiadis, D | 1 |
| Haberl, RL | 1 |
| Stiefelhagen, P | 1 |
| Diener, HC | 3 |
| Kaźmierski, MK | 1 |
| Andresen, R | 1 |
| Roth, M | 1 |
| Brinckmann, W | 1 |
| Arnold, M | 1 |
| Lyrer, P | 1 |
| Norrving, B | 1 |
| Barth, A | 1 |
| Replogle, RE | 1 |
| Rappard, G | 1 |
| Graybeal, CL | 1 |
| White, J | 1 |
| Purdy, P | 1 |
| McKevitt, FM | 2 |
| Macdonald, S | 1 |
| Venables, GS | 3 |
| Cleveland, TJ | 2 |
| Gaines, PA | 3 |
| Warlow, C | 1 |
| Webster, SE | 1 |
| Payne, DA | 1 |
| Jones, CI | 1 |
| Hayes, PD | 1 |
| Bell, PR | 1 |
| Goodall, AH | 1 |
| Sattler, KJ | 1 |
| Woodrum, JE | 1 |
| Galili, O | 1 |
| Olson, M | 1 |
| Samee, S | 1 |
| Meyer, FB | 1 |
| Zhu, XY | 1 |
| Lerman, LO | 1 |
| Lerman, A | 1 |
| Schellinger, PD | 1 |
| Hacke, W | 2 |
| Habets, PC | 1 |
| Lanthier, S | 1 |
| Armstrong, D | 1 |
| Domi, T | 1 |
| deVeber, G | 1 |
| Sherif, C | 1 |
| Dick, P | 2 |
| Sabeti, S | 2 |
| Mlekusch, W | 2 |
| Amighi, J | 2 |
| Ahmadi, R | 1 |
| Lalouschek, W | 1 |
| Minar, E | 2 |
| Schillinger, M | 2 |
| Droste, DW | 3 |
| Kaps, M | 3 |
| Siebler, M | 2 |
| Ringelstein, EB | 2 |
| Randall, MS | 1 |
| Tan, KT | 1 |
| Larroche, C | 1 |
| Chadenat, ML | 1 |
| Chaunu, MP | 1 |
| Abad, S | 1 |
| Casassus, P | 1 |
| Dhôte, R | 1 |
| McCabe, DJ | 1 |
| Harrison, P | 1 |
| Mackie, IJ | 1 |
| Sidhu, PS | 1 |
| Purdy, G | 1 |
| Lawrie, AS | 1 |
| Watt, H | 1 |
| Machin, SJ | 1 |
| Brown, MM | 1 |
| Chaturvedi, S | 2 |
| Bruno, A | 1 |
| Feasby, T | 1 |
| Holloway, R | 1 |
| Benavente, O | 2 |
| Cohen, SN | 4 |
| Cote, R | 3 |
| Hess, D | 1 |
| Saver, J | 1 |
| Stern, B | 1 |
| Wilterdink, J | 1 |
| Ouriel, K | 1 |
| Wholey, MH | 1 |
| Fayad, P | 1 |
| Katzen, BT | 1 |
| Whitlow, P | 1 |
| Frentzko, M | 1 |
| Kuntz, RE | 1 |
| Wechsler, L | 1 |
| Hopkins, N | 1 |
| Satler, L | 1 |
| Mishkel, G | 1 |
| Yadav, JS | 4 |
| Boltuch, J | 1 |
| Schlager, O | 1 |
| Ahmadi, A | 1 |
| Imray, CH | 1 |
| Higman, DJ | 1 |
| Marshall, C | 1 |
| Burgstahler, C | 1 |
| Reimann, A | 1 |
| Beck, T | 1 |
| Kuettner, A | 1 |
| Heuschmid, M | 1 |
| Kopp, AF | 1 |
| Schroeder, S | 1 |
| Dittrich, R | 1 |
| Ritter, MA | 1 |
| Lees, K | 1 |
| Nabavi, DG | 1 |
| Akaji, K | 1 |
| Tanizaki, Y | 1 |
| Hiraga, K | 1 |
| Akiyama, T | 1 |
| Dembo, T | 1 |
| Dalainas, I | 1 |
| Nano, G | 1 |
| Kikuta, K | 1 |
| Takagi, Y | 1 |
| Arakawa, Y | 1 |
| Miyamoto, S | 1 |
| Hashimoto, N | 1 |
| Buhk, JH | 1 |
| Wellmer, A | 1 |
| Knauth, M | 1 |
| Assadian, A | 2 |
| Eidher, U | 1 |
| Senekowitsch, C | 1 |
| Rotter, R | 1 |
| Löchli, S | 1 |
| Hagmüller, GW | 2 |
| Knöbl, P | 1 |
| Roffi, M | 2 |
| Onizuka, M | 1 |
| Kazekawa, K | 1 |
| Nagata, S | 1 |
| Tsutsumi, M | 1 |
| Aikawa, H | 1 |
| Tomokiyo, M | 1 |
| Iko, M | 1 |
| Kodama, T | 1 |
| Nii, K | 1 |
| Tanaka, A | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Wong, S | 1 |
| Ward, CM | 1 |
| Appleberg, M | 1 |
| Lewis, DR | 1 |
| Grond, M | 1 |
| Holten, KB | 1 |
| Viñuela, F | 1 |
| Murayama, Y | 1 |
| Yuki, I | 1 |
| Nien, YL | 1 |
| Yeh, DT | 1 |
| Vinters, HV | 1 |
| Kramer, J | 1 |
| Abraham, J | 1 |
| Teven, CM | 1 |
| Jones, PA | 1 |
| Telman, G | 1 |
| Kouperberg, E | 1 |
| Schlesinger, I | 1 |
| Yarnitsky, D | 1 |
| Kahraman, G | 1 |
| Sahin, T | 1 |
| Kilic, T | 1 |
| Baytugan, NZ | 1 |
| Agacdiken, A | 1 |
| Ural, E | 1 |
| Ural, D | 1 |
| Komsuoglu, B | 1 |
| Topakian, R | 1 |
| Nussbaumer, K | 1 |
| Trenkler, J | 1 |
| Aichner, FT | 1 |
| Pyun, HW | 1 |
| Lee, DH | 1 |
| Kwon, SU | 1 |
| Lee, JH | 1 |
| Choi, CG | 1 |
| Kim, SJ | 1 |
| Suh, DC | 1 |
| Penz, SM | 1 |
| Reininger, AJ | 1 |
| Toth, O | 1 |
| Deckmyn, H | 1 |
| Brandl, R | 1 |
| Siess, W | 1 |
| Inoue, T | 1 |
| Shimizu, H | 1 |
| Okabe, H | 1 |
| Tominga, T | 1 |
| Lax, J | 1 |
| Meixner-Loicht, U | 1 |
| Bayer, PM | 1 |
| Hübl, W | 1 |
| Rajamani, K | 1 |
| McClelland, S | 1 |
| Rothwell, PM | 2 |
| Gao, L | 1 |
| Wang, PP | 1 |
| Liu, Q | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Robicsek, F | 1 |
| Battista, RN | 1 |
| Abrahamowicz, M | 1 |
| Langlois, Y | 1 |
| Bourque, F | 1 |
| Mackey, A | 1 |
| Brott, T | 2 |
| Toole, JF | 3 |
| Schelp, R | 1 |
| Bickel, A | 1 |
| Kolominsky, P | 1 |
| Schweiger, H | 1 |
| Gorelick, PB | 1 |
| Rohack, JJ | 1 |
| Solomon, DH | 2 |
| Feinberg, WM | 1 |
| Moore, WS | 3 |
| Barnett, HJ | 1 |
| Beebe, HG | 1 |
| Bernstein, EF | 2 |
| Brener, BJ | 1 |
| Caplan, LR | 1 |
| Day, A | 1 |
| Goldstone, J | 2 |
| Hobson, RW | 7 |
| Chaudhuri, A | 1 |
| Medhekar, TP | 1 |
| Stähelin, HB | 1 |
| Evison, J | 1 |
| Seiler, WO | 1 |
| Towne, JB | 2 |
| Weiss, DG | 5 |
| Cohen, SL | 1 |
| Starling, MR | 1 |
| Lagneau, P | 1 |
| Chimowitz, M | 1 |
| Fujimura, M | 1 |
| Mikashima, H | 1 |
| Bischof, G | 1 |
| Pratschner, T | 1 |
| Kail, M | 1 |
| Mittlböck, M | 1 |
| Turkof, E | 1 |
| Puig, S | 1 |
| Polterauer, P | 1 |
| Kretschmer, G | 1 |
| Hansen, F | 1 |
| Lindblad, B | 1 |
| Persson, NH | 1 |
| Bergqvist, D | 1 |
| Britton, M | 1 |
| Fields, WS | 1 |
| Wright, CB | 1 |
| Krupski, WC | 2 |
| Hertzer, NR | 1 |
| Frey, JL | 1 |
| Browner, WS | 1 |
| Creutzig, A | 2 |
| Ranke, C | 2 |
| Goldstein, LB | 1 |
| Bonito, AJ | 1 |
| Matchar, DB | 1 |
| Duncan, PW | 1 |
| Samsa, GP | 1 |
| Sivaguru, A | 1 |
| Beard, JD | 1 |
| Diethrich, EB | 1 |
| Ndiaye, M | 1 |
| Reid, DB | 1 |
| Martín, R | 1 |
| Donati, F | 1 |
| Regli, F | 1 |
| Regli, L | 1 |
| Bogousslavsky, J | 1 |
| Sonne, M | 1 |
| Siemens, HJ | 1 |
| Young, B | 1 |
| Robertson, JT | 1 |
| Ernst, CB | 1 |
| Broderick, JP | 1 |
| Dempsey, RJ | 1 |
| Hosking, JD | 1 |
| Valentin, JP | 1 |
| Vieu, S | 1 |
| Bertolino, F | 1 |
| Fauré, P | 1 |
| John, GW | 1 |
| Biller, J | 2 |
| Calvey, TA | 1 |
| Gough, MJ | 1 |
| McNeely, W | 1 |
| Goa, KL | 1 |
| Molloy, J | 1 |
| Martin, JF | 1 |
| Baskerville, PA | 1 |
| Fraser, SC | 1 |
| Baeumer, M | 1 |
| Kross, R | 1 |
| Blaser, T | 2 |
| Lutze, G | 2 |
| Jost, S | 1 |
| Wallesch, CW | 2 |
| Mattle, HP | 1 |
| Schroth, G | 1 |
| Riggs, PN | 1 |
| DeWeese, JA | 1 |
| Loftus, CM | 1 |
| Patel, ST | 1 |
| Haser, PB | 1 |
| Korn, P | 1 |
| Bush, HL | 1 |
| Deitch, JS | 1 |
| Kent, KC | 1 |
| Shah, MV | 1 |
| Masson, C | 1 |
| Vallée, JP | 1 |
| Klijn, CJ | 1 |
| van Buren, PA | 1 |
| Kappelle, LJ | 1 |
| Tulleken, CA | 1 |
| Eikelboom, BC | 1 |
| Algra, A | 1 |
| van Gijn, J | 1 |
| Ragni, M | 2 |
| Golino, P | 2 |
| Cirillo, P | 1 |
| Scognamiglio, A | 1 |
| Piro, O | 1 |
| Esposito, N | 1 |
| Battaglia, C | 1 |
| Botticella, F | 1 |
| Ponticelli, P | 1 |
| Ramunno, L | 1 |
| Chiariello, M | 2 |
| Steinberg, J | 1 |
| Baker, WH | 1 |
| Howard, VJ | 1 |
| Howard, G | 1 |
| El Ramahi, KM | 1 |
| Al Rayes, HM | 1 |
| Krueger, S | 1 |
| Mukherjee, D | 2 |
| Chew, DP | 2 |
| Robbins, M | 1 |
| Raymond, RE | 1 |
| Moliterno, DJ | 1 |
| Weisser, B | 1 |
| Düsing, R | 1 |
| Mengden, T | 1 |
| Bhatt, DL | 1 |
| Kapadia, SR | 1 |
| Bajzer, CT | 1 |
| Ziada, KM | 1 |
| Topol, EJ | 1 |
| Grønholdt, ML | 1 |
| Nordestgaard, BG | 1 |
| Bentzon, J | 1 |
| Wiebe, BM | 1 |
| Zhou, J | 1 |
| Falk, E | 1 |
| Prieto, AR | 1 |
| Ma, H | 1 |
| Huang, R | 1 |
| Khan, G | 1 |
| Schwartz, KA | 1 |
| Hage-Korban, EE | 1 |
| Schmaier, AH | 1 |
| Davis, JM | 1 |
| Hasan, AA | 1 |
| Abela, GS | 1 |
| Rapp, JH | 1 |
| Corson, JD | 1 |
| Hecker, H | 1 |
| Alexander, K | 1 |
| Harker, LA | 1 |
| Dilley, RB | 1 |
| Scala, TE | 1 |
| Sise, MJ | 1 |
| Hye, RJ | 1 |
| Otis, SM | 1 |
| Roberts, RS | 1 |
| Gent, M | 1 |
| Schulze, HE | 1 |
| Ebner, A | 1 |
| Besinger, UA | 1 |
| Wilcox, M | 1 |
| Willette, RN | 1 |
| Sauermelch, CF | 1 |
| Rycyna, R | 1 |
| Sarkar, S | 1 |
| Feuerstein, GZ | 1 |
| Nichols, AJ | 1 |
| Ohlstein, EH | 1 |
| Ambrosio, G | 1 |
| Pascucci, I | 1 |
| Russolillo, E | 1 |
| Bolt, M | 1 |
| Floeter, MK | 1 |
| Leblhuber, F | 1 |
| Költringer, P | 1 |
| Reisecker, F | 1 |
| Duprez, D | 1 |
| Clement, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429] | Phase 3 | 11,016 participants (Actual) | Interventional | 2018-01-22 | Completed | ||
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis[NCT00805311] | Phase 4 | 400 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Due to the clear advantage of carotid endarterectomy) | ||
| Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis[NCT00576693] | Phase 3 | 451 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Stroke Imaging Package Study of Intracranial Atherosclerosis[NCT03719820] | 550 participants (Anticipated) | Observational [Patient Registry] | 2018-11-14 | Recruiting | |||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| Evolocumab Added to Statin Therapy in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)---a Pilot Study[NCT05741086] | Phase 3 | 80 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | ||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301] | 1,140 participants (Anticipated) | Observational | 2021-09-02 | Recruiting | |||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome[NCT04053894] | 220 participants (Anticipated) | Observational | 2019-08-31 | Not yet recruiting | |||
| Focal Cerebral Arteriopathy Steroid Trial[NCT06040255] | Phase 4 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| Body Cooling During Carotid Endarterectomy: No-profit, Open, Mono-centric, Feasibility Study[NCT02629653] | 10 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| Evaluation of Diagnostic and Predictive Capabilities of Novel Application of Carotid Carotid Stenosis Pressure Gradient Measurement in Patients Undergoing Percutaneous Carotid Angioplasty and Stenting (CAS).[NCT06123767] | 200 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Risk Factors for Complications After Carotid Endarterectomy: A Multicenter International Observational Study[NCT03788980] | 10 participants (Actual) | Observational | 2018-04-13 | Terminated (stopped due to Lack of funding and resources) | |||
| Radial Versus Femoral Access For Carotid Artery Stenting In Patients With Carotid-Artery Stenosis ：a Prospective, Randomized, Multicenter, Noninferiority Trial[NCT05416853] | 2,688 participants (Anticipated) | Interventional | 2022-07-04 | Recruiting | |||
| Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)[NCT02603406] | Phase 2 | 44 participants (Actual) | Interventional | 2016-07-15 | Completed | ||
| Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty[NCT00597974] | 108 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| [NCT00000527] | Phase 2 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 36 |
| PLACEBO | 11 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 28 |
| PLACEBO | 7 |
Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 303 |
| PLACEBO | 362 |
Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 22 |
| PLACEBO | 6 |
Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 276 |
| PLACEBO | 345 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 1282 |
| PLACEBO | 1284 |
Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 152 |
| PLACEBO | 32 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up. (NCT00576693)
Timeframe: Mean length of follow-up was 2.4 years
| Intervention | participants (Number) |
|---|---|
| Intensive Medical Management Plus Stenting | 52 |
| Intensive Medical Management Alone | 34 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
45 reviews available for aspirin and Carotid Artery Narrowing
| Article | Year |
|---|---|
Platelet Biomarkers in Patients with Atherosclerotic Extracranial Carotid Artery Stenosis: A Systematic Review.
Topics: Aspirin; Biomarkers; Blood Platelets; Carotid Stenosis; Humans; Platelet Aggregation Inhibitors; Str | 2022 |
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi | 2022 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
Topics: Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2019 |
The challenge of stroke prevention with intracranial arterial stenosis.
Topics: Aspirin; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Constriction, Pathologic; Drug Thera | 2013 |
Antiplatelet therapy to prevent recurrent stroke: Three good options.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Secon | 2013 |
Sex differences in stroke.
Topics: Acute Disease; Age Factors; Animals; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular | 2008 |
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, | 2009 |
Asymptomatic carotid stenosis: natural history versus therapy.
Topics: Aspirin; Atherosclerosis; Carotid Stenosis; Endarterectomy, Carotid; Fibrinolytic Agents; Humans; St | 2010 |
[Treatment for cervical carotid artery stenosis using evidenced-based medicine].
Topics: Angioplasty; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Evidence-Based Medicine; Humans; Ra | 2010 |
Prevention of stroke following transient ischemic attack.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Clin | 2011 |
[Review of major randomized clinical trials: carotid endarterectomy versus drug therapy].
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Platelet Aggregation Inhibitors; Randomi | 2011 |
Carotid endarterectomy plus medical therapy or medical therapy alone for carotid artery stenosis in symptomatic or asymptomatic patients: a meta-analysis.
Topics: Aspirin; Asymptomatic Diseases; Carotid Stenosis; Endarterectomy, Carotid; Humans; Life Style; Rando | 2012 |
The management of stroke patients by neurologists: common questions and new observations.
Topics: Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Case Management; Cl | 2002 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorv | 2003 |
[Stenosis of the carotid arteries].
Topics: Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy; Humans; Recurrence; | 2003 |
[Stroke prevention].
Topics: Administration, Oral; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Cont | 2003 |
[Lacunar infarcts].
Topics: Adult; Aged; Aspirin; Autopsy; Brain; Carotid Stenosis; Cerebral Infarction; Dementia; Female; Fibri | 2003 |
[Carotid stenosis: diagnosis, patient selection, therapy].
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Carotid St | 2003 |
Stroke: advances in therapy.
Topics: Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Drug Thera | 2005 |
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog | 2005 |
Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Topics: Aspirin; Carotid Stenosis; Causality; Clinical Trials as Topic; Dose-Response Relationship, Drug; En | 2005 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
Prevention of ischemic stroke: surgery.
Topics: Aspirin; Brain Ischemia; Carotid Artery, External; Carotid Artery, Internal; Carotid Stenosis; Coron | 2007 |
[What should be done after the first TIA?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopi | 2007 |
Multimodality management of carotid artery stenosis: reviewing the class-I evidence.
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endarterectomy, Carotid; | 2007 |
Medical compared with surgical treatment of asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modality Therapy; Endarterectomy, Car | 1995 |
[Spontaneous and heparin-induced recanalization of the completely occluded internal carotid artery--a neglected phenomenon? 2 case reports and review of the literature].
Topics: Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Combined Modality Therapy | 1995 |
Stroke prevention.
Topics: Alcohol Drinking; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1995 |
What's new in stroke?
Topics: Acute Disease; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrova | 1995 |
Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Combined Modality Th | 1995 |
Aspirin in asymptomatic carotid disease.
Topics: Aspirin; Brain Ischemia; Carotid Artery Diseases; Carotid Stenosis; Cerebrovascular Disorders; Human | 1994 |
[Prevention of cerebrovascular insults].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebral Infarction; Diet; Fem | 1994 |
[Asymptomatic carotid stenoses. Analysis of randomized studies].
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Randomized Co | 1993 |
Death associated with asymptomatic carotid artery stenosis: long-term clinical evaluation. VA Cooperative Study 167 Group.
Topics: Aged; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Follow-Up Studies; Humans; Male; Middle Ag | 1993 |
[Carotid endarterectomy--results of current studies and their consequences].
Topics: Aspirin; Carotid Stenosis; Cerebral Infarction; Clinical Trials as Topic; Endarterectomy, Carotid; H | 1993 |
Asymptomatic carotid stenosis: surgery's the answer, but that's not the question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; | 1996 |
[Treatment protocol of cerebral vascular accident].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clinical Protocols; Endarterectomy; Human | 1997 |
Triflusal.
Topics: Adult; Angina Pectoris; Animals; Aspirin; Carotid Stenosis; Humans; In Vitro Techniques; Middle Aged | 1998 |
The crucial, controversial carotid artery. Part II: Treatment.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Ischemic Attack, Trans | 1998 |
Carotid endarterectomy.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Pressure; Car | 1998 |
Stroke: part I. A clinical update on prevention.
Topics: Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; | 1999 |
Indications for treatment of symptomatic atherosclerotic carotid artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery, Internal; Carotid Stenosis; | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Carotid artery disease: when and how to treat?
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Hum | 1991 |
50 trials available for aspirin and Carotid Artery Narrowing
| Article | Year |
|---|---|
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.
Topics: Aspirin; Atherosclerosis; Atrial Fibrillation; Carotid Stenosis; Double-Blind Method; Drug Therapy, | 2020 |
Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, | 2020 |
Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dual Anti-Platelet | 2021 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
Optimal medical treatment versus carotid endarterectomy: the rationale and design of the Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) study.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Carotid Stenosis; Combined Modality Therapy; Endartere | 2015 |
Long-term effect of carotid surgery in asymptomatic stenosis.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Female; | 2012 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Female; Follow- | 2014 |
Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting.
Topics: Angiography; Aspirin; Breath Tests; Carotid Arteries; Carotid Stenosis; Clopidogrel; Drug Interactio | 2013 |
Influence of carotid artery stenting on cognition of elderly patients with severe stenosis of the internal carotid artery.
Topics: Aged; Analysis of Variance; Angioplasty; Aspirin; Atorvastatin; Carotid Stenosis; China; Clopidogrel | 2014 |
Aterofisiol(®) in carotid plaque evolution.
Topics: Adult; Aged; Aspirin; Carotid Stenosis; Dietary Supplements; Double-Blind Method; Endarterectomy, Ca | 2015 |
Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?
Topics: Angioplasty; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Constriction, Patholo | 2015 |
Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.
Topics: Aspirin; Carotid Artery, Common; Carotid Stenosis; Clopidogrel; Dose-Response Relationship, Drug; En | 2016 |
[Prevalence of acetylsalicylic acid (ASA) - low response in vascular surgery].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Stenosi | 2016 |
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co | 2016 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial.
Topics: Adult; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Drug Therapy, Combina | 2010 |
Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke o
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Arteries; Carotid Stenosis; Data Interpre | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Carotid Stenosis; Drug Interactions; Endarterect | 2004 |
Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C- | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Embolism; | 2005 |
The benefits of combined anti-platelet treatment in carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Female; | 2005 |
[Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis].
Topics: Adult; Aged; Aspirin; C-Reactive Protein; Carotid Stenosis; Cerebrovascular Disorders; Clopidogrel; | 2008 |
Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Double-Blind Method; Female; Gast | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.
Topics: Adult; Aged; Angiography; Aspirin; Carotid Stenosis; Cerebral Infarction; Endarterectomy; Female; Fo | 1995 |
The effect of aspirin on neurodeficit and platelet aggregability in acute ischemic cerebral strokes.
Topics: Adult; Aged; Aspirin; Carotid Stenosis; Cerebral Infarction; Dose-Response Relationship, Drug; Femal | 1994 |
4. Current status of operative treatment for asymptomatic carotid stenosis.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modality Therapy; Endarterectomy, Car | 1994 |
Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167.
Topics: Aged; Aspirin; Carotid Stenosis; Coronary Disease; Endarterectomy, Carotid; Humans; Male; Middle Age | 1994 |
Death associated with asymptomatic carotid artery stenosis: long-term clinical evaluation. VA Cooperative Study 167 Group.
Topics: Aged; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Follow-Up Studies; Humans; Male; Middle Ag | 1993 |
Can recurrent stenosis after carotid endarterectomy be prevented by low-dose acetylsalicylic acid? A double-blind, randomised and placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Dose-Response R | 1993 |
Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group.
Topics: Adult; Aspirin; Blindness; Carotid Arteries; Carotid Stenosis; Cerebrovascular Disorders; Endarterec | 1993 |
Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis.
Topics: Aspirin; Carotid Artery, External; Carotid Stenosis; Cerebrovascular Disorders; Chi-Square Distribut | 1993 |
European carotid angioplasty trial.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Carotid Artery, | 1996 |
Asymptomatic circulating cerebral emboli and cerebral blood flow velocity under aspirin and ticlopidine in patients with cerebrovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Flow Velocity; Carotid Stenosis; Cell Survival; Cereb | 1996 |
An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality Ther | 1996 |
S-nitrosoglutathione reduces the rate of embolization in humans.
Topics: Aged; Anticoagulants; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Female; Glutathione; Hepar | 1998 |
Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid.
Topics: Adult; Aged; Aspirin; Carotid Stenosis; Cerebral Arteries; Cerebrovascular Disorders; Female; Fibrin | 1999 |
Assessment of >/=50% and <50% intracranial stenoses by transcranial color-coded duplex sonography.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Stenosis; Cerebral Angi | 1999 |
Current indications for carotid endarterectomy.
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Flurbiprofen; Humans; Prospective Studies; Sever | 1998 |
Is carotid endarterectomy cost-effective in symptomatic patients with moderate (50% to 69%) stenosis?
Topics: Aged; Aspirin; Carotid Stenosis; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; | 1999 |
[What dose of acetylsalicylic acid to use after carotid endarterectomy?].
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet Aggregat | 2000 |
Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators.
Topics: Aged; Arteriosclerosis; Aspirin; Carotid Stenosis; Disease-Free Survival; Endarterectomy, Carotid; F | 2000 |
Acetylsalicylic acid and microembolic events detected by transcranial Doppler in symptomatic arterial stenoses.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebrovascular Circulation; Female; Humans; Intracranial Embolism | 2001 |
Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis. The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group.
Topics: Aged; Analysis of Variance; Aspirin; Carotid Stenosis; Chi-Square Distribution; Combined Modality Th | 1992 |
Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Female; Follow- | 1992 |
[Dose-dependent inhibition of plaque growth in the carotid artery by acetylsalicylic acid].
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Dose-Response Relationship, Drug; Double-Blind Meth | 1992 |
Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combination; | 1992 |
Asymptomatic carotid atherosclerosis study: role of the clinical coordinator.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modali | 1992 |
Carotid endarterectomy.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans | 1992 |
Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group.
Topics: Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Cerebrovascular Dis | 1991 |
125 other studies available for aspirin and Carotid Artery Narrowing
| Article | Year |
|---|---|
Efficacy and safety of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endovascular Procedures; Femoral Artery; H | 2022 |
Dual Antiplatelet Therapy Is Associated with Increased Risk of Bleeding and Decreased Risk of Stroke Following Carotid Endarterectomy.
Topics: Aspirin; Carotid Stenosis; Coronary Artery Disease; Endarterectomy, Carotid; Humans; Platelet Aggreg | 2023 |
Insurance status is associated with urgent carotid endarterectomy and worse postoperative outcomes.
Topics: Aged; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Hydroxymethylglutaryl-CoA Reductas | 2023 |
Aspirin versus aggressive antiplatelet therapy for acute carotid stenting plus thrombectomy in tandem occlusions: ETIS Registry results.
Topics: Aspirin; Carotid Stenosis; Endovascular Procedures; Humans; Ischemic Stroke; Platelet Aggregation In | 2023 |
Efficacy and safety of single versus dual antiplatelet therapy in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Re | 2023 |
High-on-treatment platelet reactivity predicts adverse outcome after carotid artery stenting: A prospective study.
Topics: Aspirin; Blood Platelets; Carotid Arteries; Carotid Stenosis; Humans; Percutaneous Coronary Interven | 2023 |
Impact of continued clopidogrel use on outcomes of patients undergoing carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; Humans; Male; Myocard | 2023 |
Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Carotid Stenosis; Female; Humans; Intracranial Embol | 2020 |
Dual energy CT in the management of antiplatelet therapy in patients with acute ischemic stroke for carotid obstruction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cerebral Hemorrhage; Clopidogrel; Female; | 2020 |
Focal Cerebral Arteriopathy in Young Adult Patients With Stroke.
Topics: Acyclovir; Adult; Antibodies, Viral; Antiviral Agents; Aspirin; Carotid Artery, Internal; Carotid St | 2020 |
Antiplatelet Therapy During Emergent Extracranial Internal Carotid Artery Stenting: Comparison of Three Intravenous Antiplatelet Perioperative Strategies.
Topics: Abciximab; Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Carotid Artery, Inte | 2021 |
Perioperative changes of response to antiplatelet medication in vascular surgery patients.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Empirical Research; Female; Humans; | 2020 |
Adjunctive treatment with low dose intra-arterial eptifibatide and intravenous aspirin during carotid stenting: A case series.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Endovascular Procedures; Eptifibatide; Female; Humans; | 2021 |
Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Female; Humans; Male; Middle Aged; | 2021 |
Platelet Function Monitoring Performed after Carotid Stenting during Endovascular Stroke Treatment Predicts Outcome.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Databases, Factual; Disability Evaluation; Drug Monito | 2021 |
Screening for Asymptomatic Carotid Artery Stenosis: Recommendation Statement.
Topics: Aged; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Carotid Stenosis; Health Behavior; He | 2021 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Assessment of 'on-treatment platelet reactivity' and relationship with cerebral micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
Topics: Aged; Aspirin; Brain; Carotid Stenosis; Case-Control Studies; Clopidogrel; Disease Progression; Fema | 2017 |
Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers.
Topics: Aged; Algorithms; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Carotid Stenosis; | 2018 |
Acute administration of tirofiban versus aspirin in emergent carotid artery stenting.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebral Angiography; Female; Fibrinolytic Agents; Humans; Male; Mi | 2019 |
Critical reversible bilateral internal carotid artery stenosis associated with SLE.
Topics: Adult; Antirheumatic Agents; Aspirin; Carotid Stenosis; Drug Therapy, Combination; Female; Glucocort | 2013 |
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Revascularizatio | 2014 |
Progression of asymptomatic carotid stenosis despite optimal medical therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Asymptomatic Diseases; Biomarkers; Cardiovascular Agents; Carotid | 2013 |
Efficacy of contemporary medical management for asymptomatic carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2013 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag | 2014 |
Is carotid ultrasound necessary in the evaluation of the asymptomatic Hollenhorst plaque?
Topics: Arterioles; Aspirin; Asymptomatic Diseases; Carotid Arteries; Carotid Stenosis; Endarterectomy, Caro | 2013 |
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Ther | 2014 |
Prospective registry of carotid artery stenting in Japan--investigation on device and antiplatelet for carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Cilostazol; Clopidogrel; Drug | 2014 |
Regarding "Progression of asymptomatic carotid stenosis despite optimal medical therapy".
Topics: Aspirin; Cardiovascular Agents; Carotid Stenosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2014 |
Reply: To PMID 23806255.
Topics: Aspirin; Cardiovascular Agents; Carotid Stenosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2014 |
The natural history of asymptomatic severe carotid artery stenosis.
Topics: Aged; Aspirin; Asymptomatic Diseases; Blood Flow Velocity; Cardiovascular Agents; Carotid Stenosis; | 2014 |
Thrombolysis May Reduce the Incidence/Extent of Postprocedural Ischemic Strokes Associated With Carotid Artery Stenting: A Hypothesis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Hydroxy | 2015 |
Evaluation of aspirin resistance and the presence of unstable carotid plaque in patients undergoing carotid endarterectomy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Carotid Stenosis; Endarterectomy, Carotid; | 2015 |
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A | 2015 |
Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2016 |
Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
Topics: Aged; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Female; Follow-Up Studies; Humans; M | 2015 |
Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Dia | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study.
Topics: Aged; Aspirin; Blood Loss, Surgical; Carotid Stenosis; China; Clopidogrel; Drug Therapy, Combination | 2016 |
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogr | 2017 |
Combined carotid stenting and urgent coronary artery surgery in unstable angina patients with severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid St | 2009 |
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S | 2009 |
[Diagnostics and treatment of carotidynia--rare angiological disease].
Topics: Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery Diseases; Carotid Arte | 2009 |
Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies.
Topics: Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Feasibilit | 2010 |
[Beyond coronary artery disease: interventional approach to carotid occlusive disease].
Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Arte | 2010 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid St | 2011 |
Have medical therapy and stenting been fairly compared? A repercussion upon termination of recruitment in the SAMMPRIS trial.
Topics: Angioplasty; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Humans; National Inst | 2011 |
Microembolic signals and aspirin resistance in patients with carotid stenosis.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Monitoring; Drug | 2012 |
Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting.
Topics: Aspirin; Body Mass Index; Body Weight; Carotid Stenosis; Cerebrovascular Disorders; Clopidogrel; Fem | 2011 |
Blind runner.
Topics: Adult; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Hum | 2012 |
Editorial - do not throw the baby out with the bathwater….
Topics: Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Humans; Multicenter Studies as Topic; National | 2011 |
Transient ischemic attacks in a 22-year-old.
Topics: Anticoagulants; Aspirin; Carotid Stenosis; Diagnosis, Differential; Female; Glucocorticoids; Heparin | 2012 |
Perioperative use of aspirin for patients undergoing carotid endarterectomy.
Topics: Administration, Oral; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Administration | 2012 |
Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery Thrombosis; C | 2013 |
Continued concern about parent vessel steno-occlusive progression with Onyx HD-500 and the utility of quantitative magnetic resonance imaging in serial assessment.
Topics: Angioplasty; Aspirin; Carotid Artery Diseases; Carotid Stenosis; Clopidogrel; Constriction, Patholog | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines | 2013 |
[Transient cerebral ischemia--precursors of stroke. Can warning signs be recognized?].
Topics: Aspirin; Brain; Carotid Stenosis; Cerebral Infarction; Diagnostic Imaging; Exercise; Humans; Ischemi | 2003 |
[Stroke is not equal to stroke. Keep track of the causes].
Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
[Outpatient primary stent-angioplasty in symptomatic internal carotid artery stenoses].
Topics: Aged; Angiography; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid | 2003 |
Stent-coil treatment of a distal internal carotid artery dissecting pseudoaneurysm on a redundant loop by use of a flexible, dedicated nitinol intracranial stent.
Topics: Adult; Alloys; Aneurysm, False; Aspirin; Carotid Artery, Internal, Dissection; Carotid Stenosis; Com | 2004 |
Is the endovascular treatment of carotid stenosis in high-risk patients really safer than carotid endarterectomy?
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Carotid Stenosis; Endarterectomy, Car | 2004 |
The Willis Lecture 2003: evaluating treatments for stroke patients too slowly: time to get out of second gear.
Topics: Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Clinical Trials as | 2004 |
[Carotid endarterectomy indicated in asymptomatic stenosis].
Topics: Aspirin; Carotid Artery, Internal; Carotid Stenosis; Endarterectomy, Carotid; Humans; Risk Factors; | 2004 |
Neurological outcome of conservative versus endovascular treatment of patients with asymptomatic high-grade carotid artery stenosis: a propensity score-adjusted analysis.
Topics: Aged; Angioplasty; Aspirin; Carotid Stenosis; Clopidogrel; Disease-Free Survival; Female; Follow-Up | 2005 |
[Strokes associated with cervical artery dissection, and systemic mastocytosis: an unfortuitous association? A report of two cases].
Topics: Aspirin; Brain Infarction; Carotid Artery, Internal, Dissection; Carotid Stenosis; Clopidogrel; Fibr | 2005 |
Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.
Topics: Acute Disease; Aged; Aspirin; Carotid Stenosis; Female; Fibrinolytic Agents; Flow Cytometry; Humans; | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Procedure-related complications and early neurological adverse events of unprotected and protected carotid stenting: temporal trends in a consecutive patient series.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Internal; Carotid Stenosis; Clo | 2005 |
Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Platelet Aggreg | 2005 |
Letter regarding article by Markus et al, "Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic cardiac stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Platelet Aggreg | 2005 |
Imaging of a regressive coronary soft plaque under lipid lowering therapy by multi-slice computed tomography.
Topics: Aspirin; Atorvastatin; Carotid Stenosis; Coronary Artery Disease; Drug Therapy, Combination; Heptano | 2006 |
The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Humans; Intracranial Embolism; Multicenter Studies as Topic; | 2006 |
[A case of carotid stenting via the transbrachial approach in the bovine arch].
Topics: Aged; Aspirin; Brachial Artery; Carotid Artery, Common; Carotid Artery, Internal; Carotid Stenosis; | 2006 |
Compatibility of carotid stenting and cardiac surgery.
Topics: Aspirin; Blood Loss, Surgical; Carotid Arteries; Carotid Stenosis; Humans; Platelet Aggregation Inhi | 2006 |
Absence epilepsy associated with moyamoya disease. Case report.
Topics: Anticonvulsants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Cerebral | 2006 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2006 |
Antiplatelet therapy prior to carotid endarterectomy--still room for improvement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Austria; Carotid Artery, Internal; Carotid Stenosis; Clopid | 2006 |
Carotid stenting.
Topics: Aged; Aspirin; Cardiovascular Agents; Carotid Artery, Internal; Carotid Stenosis; Clopidogrel; Endar | 2006 |
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St | 2006 |
Point of care testing of aspirin resistance in patients with vascular disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Artery, Internal; | 2006 |
[Guidelines given by the DSG and DGN concerning stroke therapy--new therapeutic aspects].
Topics: Aged; Antihypertensive Agents; Aspirin; Carotid Stenosis; Cerebral Infarction; Combined Modality The | 2006 |
Endarterectomy for carotid artery stenosis: who qualifies?
Topics: Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Humans; Patient Selection; Platelet Aggregation | 2006 |
Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia.
Topics: Angiography; Angioplasty, Balloon; Animals; Aspirin; Calcinosis; Carotid Arteries; Carotid Artery In | 2006 |
Role of antiplatelets in carotid artery stenting.
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Dipyridamole | 2007 |
Cessation of microemboli in the middle cerebral artery after a single dose of aspirin in a young patient with emboliogenic lacunar syndrome of carotid origin.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Infar | 2006 |
The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Stenosis; Cross-Sectional Studies; Dose-Respo | 2007 |
Late in-stent thrombosis following carotid angioplasty and stenting.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Anticoagulants; Aph | 2007 |
Internal carotid artery stenosis with ipsilateral persistent hypoglossal artery presenting as a multiterritorial embolic infarction: a case report.
Topics: Aged; Aspirin; Basilar Artery; Brain; Carotid Artery, Internal; Carotid Stenosis; Cerebral Infarctio | 2007 |
Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Atherosclerosis; Bl | 2007 |
Amaurosis fugax caused by retinal artery vasospasm. Case illustration.
Topics: Adult; Amaurosis Fugax; Aspirin; Calcium Channel Blockers; Carotid Artery, Internal; Carotid Stenosi | 2007 |
Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition.
Topics: Aged; Arachidonic Acid; Aspirin; Blood Platelets; Carotid Stenosis; Case-Control Studies; Cyclooxyge | 2007 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Operative indication in asymptomatic carotid arterial disease.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Gui | 1995 |
Can overall results of clinical trials be applied to all patients?
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectomy, Caro | 1995 |
Effect of Y-20811, a thromboxane synthetase inhibitor, on photochemically induced cerebral embolism in rabbits.
Topics: Animals; Aspirin; Carotid Artery Thrombosis; Carotid Stenosis; Cerebral Infarction; Disease Models, | 1993 |
Anticoagulants, antiaggregants or nothing following carotid endarterectomy?
Topics: Aged; Aspirin; Carotid Stenosis; Cause of Death; Endarterectomy, Carotid; Female; Follow-Up Studies; | 1993 |
[Prevention of stroke. Blood pressure lowering changes in life style and diet are highly effective].
Topics: Anticoagulants; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Feedi | 1993 |
A personal view: the Asymptomatic Carotid Atherosclerosis Study results--read the label carefully.
Topics: Arteriosclerosis; Aspirin; Canada; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Caro | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Confidence Intervals; Humans | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Female; Humans; Male; Myocardial Infarction | 1996 |
Aspirin for asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Humans; Myocardial Infarction | 1996 |
US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebrovascular Disorders; Data Collectio | 1996 |
Stenting in the carotid artery: initial experience in 110 patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery | 1996 |
[Atrial fibrillation, carotid stenosis and stroke].
Topics: Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Cerebrovascular Disorders; Cyclooxygenase Inh | 1996 |
Considerations in the prophylactic treatment of transient ischemic attack or ischemic stroke in the carotid artery territory.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Stenosis; Cerebrovascular Disorders | 1995 |
Differential involvement of serotonin 2A/C and thromboxane A2/prostanoid receptors in high- vs. low-shear rate arterial thrombosis in rabbits.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Pressure; Bridged Bicyclo Compounds, Heterocy | 1997 |
A late complication of internal carotid artery stenting.
Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Carotid Ste | 1998 |
Outcome in patients with symptomatic occlusion of the internal carotid artery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal; Carotid Stenosis; | 2000 |
Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury.
Topics: Animals; Antibodies; Aspirin; Blood Coagulation; Blood Flow Velocity; Carotid Artery Injuries; Carot | 2000 |
Does carotid endarterectomy benefit patients with carotid stenosis but no symptoms?
Topics: Aged; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Follow-Up Stu | 2000 |
Antiplatelet drugs in cardiovascular prevention: coronary events and stroke: primary prevention.
Topics: Aspirin; Carotid Stenosis; Cost-Benefit Analysis; Diabetes Mellitus; Digestive System; Female; Human | 2000 |
Systemic lupus erythematosus associated with moyamoya syndrome.
Topics: Adolescent; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Artery, Internal; Carotid Stenos | 2000 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
[Arterial hypertension - the specific case].
Topics: Aspirin; Carotid Artery, Internal; Carotid Stenosis; Diabetes Complications; Diet; Exercise; Follow- | 2001 |
Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Combined Modality Therapy; Female; | 2001 |
Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels.
Topics: Analysis of Variance; Aspirin; Carotid Arteries; Carotid Artery Diseases; Carotid Stenosis; Endarter | 2002 |
Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury.
Topics: Animals; Aspirin; Blood Platelets; Bradykinin; Carotid Arteries; Carotid Artery Injuries; Carotid St | 2002 |
Report of dissection of the internal carotid artery in three cases.
Topics: Angiography, Digital Subtraction; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Arter | 1992 |
Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis.
Topics: Animals; Aspirin; Blood Platelets; Carotid Artery Thrombosis; Carotid Stenosis; Cerebrovascular Circ | 1992 |
Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation.
Topics: Animals; Arachidonic Acid; Aspirin; Carotid Stenosis; Disease Models, Animal; Endothelium, Vascular; | 1992 |
[30 mg acetylsalicylic acid per day is equally effective as 238 mg in patients following a transient ischemic attack or a non-invalidating brain infarct, and with fewer side effects].
Topics: Aspirin; Carotid Stenosis; Endarterectomy; Humans; Reperfusion | 1992 |
[Treatment of acute manifestation of hemichorea with aspirin. A case report].
Topics: Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Brain Ischemia; Carotid Stenosis; Chorea; Cor | 1991 |